Gainers
- TuHURA Biosciences (NASDAQ:HURA) stock increased by 17.4% to $2.46 during Wednesday's after-market session. The market value of their outstanding shares is at $104.0 million.
- SenesTech (NASDAQ:SNES) stock moved upwards by 16.23% to $2.65. The market value of their outstanding shares is at $2.7 million. As per the press release, Q4 earnings came out today.
- BioSig Technologies (NASDAQ:BSGM) stock increased by 12.64% to $0.8. The market value of their outstanding shares is at $18.4 million.
- Scienture Holdings (NASDAQ:SCNX) shares moved upwards by 12.41% to $1.46. The company's market cap stands at $12.5 million.
- cbdMD (AMEX:YCBD) shares rose 8.99% to $0.29. The company's market cap stands at $1.8 million.
- Seres Therapeutics (NASDAQ:MCRB) stock rose 8.19% to $0.75. The company's market cap stands at $128.0 million.
Losers
- Cutera (NASDAQ:CUTR) stock decreased by 52.5% to $0.05 during Wednesday's after-market session.
- Aditxt (NASDAQ:ADTX) shares declined by 39.27% to $0.03. The company's market cap stands at $2.7 million.
- Hepion Pharmaceuticals (NASDAQ:HEPA) stock decreased by 18.86% to $0.04.
- Syros Pharmaceuticals (NASDAQ:SYRS) shares fell 9.98% to $0.08. The company's market cap stands at $2.0 million.
- Biote (NASDAQ:BTMD) stock declined by 9.76% to $3.7. The company's market cap stands at $115.1 million. As per the press release, Q4 earnings came out today.
- China Pharma Holding (AMEX:CPHI) stock decreased by 7.03% to $0.25. The company's market cap stands at $4.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
BTMDBiote Corp
$2.77-3.15%
CPHIChina Pharma Holding Inc
Not Available-%
HEPAHepion Pharmaceuticals Inc
$0.0790-%
HURATuHURA Biosciences Inc
$2.38-7.75%
MCRBSeres Therapeutics Inc
$18.74-3.90%
SCNXScienture Holdings Inc
$0.7000-8.36%
SNESSenesTech Inc
$3.78-8.47%
SYRSSyros Pharmaceuticals Inc
$0.00500-%
YCBDcbdMD Inc
$1.25-13.8%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.